Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Pre-operative,Window of Opportunity Trial Investigating the Effect of Elacestrant With/Without Triptorelin in Premenopausal Patients With HR+/HER2- Breast Cancer - SOLTI-2104-PremiÈRe Trial.

NCT05982093 is registered in ClinicalTrials.gov with SOLTI Breast Cancer Research Group as lead sponsor.

NCT NCT05982093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05982093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Pre-operative,Window of Opportunity Trial Investigating the Effect of Elacestrant With/Without Triptorelin in Premenopausal Patients With HR+/HER2- Breast Cancer - SOLTI-2104-PremiÈRe Trial.
Lead sponsor
SOLTI Breast Cancer Research Group
Phase
Phase 2
Overall status
Recruiting
Start date
February 3, 2023
Completion date
December 31, 2026
Enrollment
96 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-negative breast cancer, hormone receptor positive tumor, premenopausal breast cancer